MTOR and tuberous sclerosis: In 2022, FDA registered the recent mTOR inhibitor for clinical use under the name HyftorTM of which rapamycin is an active compound in this substance to treat facial angiofibroma linked with tuberous sclerosis in children over 6 years of age and adults [241].